Invention Grant
- Patent Title: Inhibition of crystal growth of roflumilast
-
Application No.: US16136804Application Date: 2018-09-20
-
Publication No.: US10940142B2Publication Date: 2021-03-09
- Inventor: David W. Osborne
- Applicant: ARCUTIS, INC.
- Applicant Address: US CA Menlo Park
- Assignee: ARCUTIS, INC.
- Current Assignee: ARCUTIS, INC.
- Current Assignee Address: US CA Menlo Park
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- Main IPC: A61K31/44
- IPC: A61K31/44 ; C09K15/06 ; A61K47/10 ; A61K9/00 ; A61K9/06 ; A61K9/14 ; A61K45/06
Abstract:
Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
Public/Granted literature
- US20190015398A1 INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST Public/Granted day:2019-01-17
Information query
